The Sino Dutch Seminar 2013 made a significant contribution to our roadmap of ambitious development and global growth strategy in medical devices and medical device business. Polyganics creates a one of a kind bioresorbable value for different kinds of surgery (see company movie) . In our scope such a value cannot be fulfilled without involving China. In order to better understand unsolved clinical and surgical needs here, Polyganics has to collaborate strategically with the right partner. Polycare Beijing has proven operational excellence in making Polyganics’ Nasopore market leader in the Chinese nasal dressing segment, matching Stryker Instruments’ performance in the US ENT market. In order to structure also the upstream activities both companies agreed to further partner up the collaboration! In the general surgery field (e.g low carcinoma resection) mortality and high costs represent the unsolved needs, obviously; also in Asia. The C-SEAL European Phase III trial is aimed at the proof of concept in AL ( anastomotic leakage) prevention.
Shanghai September 11 2013
Christina Zhao (GM Polycare) & Gutwin Chun (Director M&S Polyganics)